Clinical Cfficacy of Methylprednisolone Sodium Succinate in the Treat-ment of Refractory Mycoplasma Pneumonia in Children and Its Impact on Inflammatory Factors
Objective To explore the role of methylprednisolone sodium succinate in children with refractory myco-plasma pneumonia.Methods A total of 108 children with mycoplasma pneumonia treated in Nanjing Gaochun People's Hospital from September 2022 to October 2023 were non-randomly selected as the study objects and divided into two groups with 54 cases each by different treatment modalities.The control group was treated with azithromycin,and the study group was treated with methylprednisolone sodium succinate intravenously.Symptom remission time,clinical efficacy,inflammatory factors and immune function were compared between the two groups.Results The symptom remission time of the study group was shorter than that of the control group,the inflammation level was lower than that of the control group,and the immune function was better than that of the control group,the differences were statistically significant(all P<0.05).The total effective rate of the study group(96.29%)was higher than that of the control group(85.19%),and the difference was statistically significant(χ2=3.967,P<0.05).Conclusion Methylpred-nisolone sodium succinate in the treatment of refractory mycoplasma pneumonia in children can alleviate inflamma-tion,improve immunity,promote symptom relief and improve clinical efficacy.
Methylprednisolone sodium succinateDifficult to treatMycoplasma pneumoniaSymptom reliefInflammatory factorsimmunity
NETL
NSTL
万方数据
